Oral lasmiditan: Completed Phase III enrollment

CoLucid completed randomization of 2,232 patients in the double-blind, placebo-controlled, U.S. Phase III SAMURAI trial evaluating 100 and 200 mg oral lasmiditan for up to 8 weeks. Each patient receiv...